Including immune response data.

In April reported Argos positive safety and feasibility data from the Phase 1 clinical trial of AGS-004 in HIV-infected adults ART The company plans to complete Phase 1 clinical trial results, including immune response data, to. To present the International AIDS Conference in August 2008.

Argos ‘ Arcelis technology platform loads autologous dendritic cells. Using patient – specific antigens from whole viral RNA, which induces extensive, potent immune targeting of different variants of the HIV virus in each patient ‘.. In some cases,utics Initiates Phase 2 proof-of-concept study for your Arcelis Personalized Immunotherapy Platform in HIVArgos Therapeutics today announced the initiation of a Phase 2a proof – of-concept study to determine the effectiveness of their AGS 004 test therapy in improving immune control of viral replication in HIV-infected adults.And there the problem. Which global visionaries enthusiasts. Enthusiasts fulfill our quick-fix philosophy. It is not only the U.S. Most of the world will in this manner.